Verifying the inhibitory effect of oxicams on the progression of Parkinson's disease using medical big data

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K16036
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: Asahikawa Medical College
• Principal Investigator: Kasamo Sachiko 旭川医科大学, 医学部, 助教 (10825227)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: パーキンソン病 / NSAIDs / レセプトデータ / 医療ビッグデータ

Outline of Final Research Achievements

Currently, the only drugs used to treat Parkinson's disease (PD) are symptomatic treatments that improve symptoms, and no drugs can slow the progression of the disease. Recent basic and animal studies have reported that non-steroidal anti-inflammatory drugs (NSAIDs), especially oxicam drugs such as meloxicam, inhibit the death of dopaminergic neurons in the brain. In this study, the original aim was to investigate the relationship between the prescription status of oxicam drugs and disease progression in patients with Parkinson's disease using the large-scale claims database. However, the number of patients who were actually prescribed oxicam drugs was rare in the present database, and it was not sufficient to verify the inhibitory effect of those drugs on the progression of Parkinson's disease. Therefore, we will continue to conduct exploratory analyses on other NSAIDs comprehensively with a new perspective.

Free Research Field

医療薬学、薬剤疫学

Academic Significance and Societal Importance of the Research Achievements

非ステロイド性抗炎症薬(NSAIDs)は臨床現場ですでに汎用されており、パーキンソン病(PD)の固縮, 無動など疾病固有の症状に伴って現れる疼痛等に対しても処方され、NSAIDs使用中のPD患者は多数存在している。本研究結果としては、本邦のPD患者におけるNSAIDsの処方内容や経年変化等の実態を示すことができた。しかし、本研究の中心的薬剤である、メロキシカムを含むオキシカム系薬剤の使用実態が少ないことが明らかとなり、当初の目的としていた対象薬剤とPD進行の関連性について検討ができなかった。今後の研究を進める際には他の薬剤とPD進行の関連性も考慮に入れた解析が求められる。